http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112384508-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate | 2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112384508-B |
| titleOfInvention | Tribicyclic ASK1 inhibitors and their applications |
| abstract | The present invention relates to compounds represented by general formula (I), pharmaceutically acceptable salts, esters or stereoisomers thereof. The present invention also relates to a preparation method of the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound. The compounds of the present invention can effectively inhibit the amino acid phosphorylation of ASK1 and inhibit the activation of ASK1; therefore, they can treat and/or prevent diseases mediated by ASK1 and related diseases. |
| priorityDate | 2018-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 137.